

**FOR IMMEDIATE RELEASE**

Contacts: Wendy Williams/Liza Heapes  
Schwartz Communications  
(781) 684-0770  
proxima@schwartz-pr.com

**FIRST THREE-YEAR DATA ON MAMMOSITE PRESENTED AT PREMIER  
RADIATION ONCOLOGY MEETING**

*One of Eight Post-Market Studies of MammoSite presented at ASTRO, Good Cosmetic  
Results and Excellent Patient Acceptance are Achieved After Three Years*

**Atlanta, GA—October 4, 2004—46<sup>th</sup> Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO)**—Proxima Therapeutics, Inc. today announced 30 month follow-up data on women treated with the MammoSite radiation therapy treatment for breast cancer. Details from this multi-center study were presented at the Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) taking place in Atlanta, October 3-7, in poster discussion titled, “Thirty Month Results with the MammoSite Breast Brachytherapy Applicator: Cosmesis, Toxicity and Local Control in Partial Breast Irradiation,” by Dr. Martin Keisch of Mount Sinai Medical Center in Miami Beach, FL. Cleared by the U.S. Food and Drug Administration (FDA) in May 2002, MammoSite has since become the most widely-used form of partial breast irradiation for the treatment of breast cancer. Doctors at hundreds of U.S. hospitals and radiation treatment facilities offer MammoSite to appropriate, early-stage patients, affording them with a targeted internal treatment delivered in five days.

“As a minimally invasive and shorter treatment option, MammoSite has been widely accepted by both doctors and patients,” said Dr. Martin Keisch, co-author of the study. “It is important to follow MammoSite patients closely to continue to gather information on their long-term outcomes and to ensure responsible application of this technology.”

“MammoSite has had a profound impact on the field of partial breast irradiation by simplifying the internal delivery of radiation and allowing patients to complete their treatment faster than with traditional whole breast radiation,” said Dr. Alan Stoller, surgeon at Louisiana State University and co-author of the study. “We are encouraged that this three year study shows women who have been treated with MammoSite have had positive results and we look forward to providing the medical community with additional long-term data as time progresses.”

Partial breast irradiation is the practice of delivering radiation only to the tissue immediately surrounding the removed tumor, where cancer is most likely to recur, thereby limiting radiation exposure to healthy tissue. The MammoSite device is a balloon catheter that is placed in the cavity created by a lumpectomy. During a five-day course of therapy, a tiny radioactive seed attached to a wire is inserted into the balloon, delivering prescribed levels of radiation under precise computer control to the targeted tissue surrounding the cavity. No source of radiation remains in the patient’s body between treatments or after the final procedure.

In this study, patients at eight U.S. hospitals and radiation facilities were treated with MammoSite in a timeframe spanning May 2000 to October 2001. Since that time, no patients in the study experienced a tumor recurrence and cosmetic outcomes were described as good-to-excellent in the vast majority of patients, with toxicity evaluated as being minimal. Additional data on MammoSite will also be provided at ASTRO in a total of eight poster discussions and panel presentations throughout the meeting.

### **About MammoSite**

MammoSite is a minimally invasive balloon catheter that is inserted into the cavity created by a lumpectomy. During a five-day course of therapy, a tiny radioactive seed attached to a wire is inserted into the balloon, delivering prescribed levels of radiation under precise computer control to the targeted tissue surrounding the cavity. No source of radiation remains in the patient's body between treatments or after the final procedure. Since its clearance by the FDA in May 2002, MammoSite has been used to treat thousands of early-stage breast cancer patients. For a list of treatment centers, refer to [www.mammosite.com](http://www.mammosite.com).

Safety and performance of MammoSite were evaluated in a multi-center study, which involved women with early-stage breast cancer. The results of the study were published in the *International Journal of Radiation Oncology\*Biological\*Physics* (February 2003).

A study published in the *Journal of the National Cancer Institute* found that, over the course of five years, partial breast irradiation produces comparable results to whole-breast radiation therapy in preventing breast cancer recurrence in women with early-stage breast cancer who are treated with breast-conserving therapy.

### **About Proxima Therapeutics, Inc.**

Based in Alpharetta, Ga., Proxima Therapeutics, Inc. is a privately held medical device company established in 1995 to develop site-specific cancer treatment systems for malignant tumors. Marketed products include MammoSite RTS for breast cancer and GlioSite RTS for brain cancer. Additional information is available on the company's Web site at [www.proximatherapeutics.com](http://www.proximatherapeutics.com). Physicians and patients may call 1-866-PROXIMA (1-866-776-9462) for more information.

###